A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

Phase 3 Recruiting 669 enrolled Haisco Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase III, single-arm, open-label, multicenter study to assess the safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.

Timeline

Start: 2025-09-28
Primary completion: 2029-01-10
Completion: 2029-04-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK31858	Unknown	40 mg	—

A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

Summary

Timeline

Drugs

Indications